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 Abstract 
Solubility is a major problem for nearly one third drugs in their development phase. Liquisolid technique is a most 
promising technique for promoting dissolution by increase in solubility. Liquisolid compact technology is a novel concept 
for oral drug delivery. Liquisolid compact technology was first described by Spireas et al (1998). According to the new 
formulation method of liqui-solid compacts, liquid medications such as solutions or suspensions of water insoluble drugs in 
suitable nonvolatile liquid vehicles can be converted into acceptably flowing and compressible powders by blending with 
selected powder excipients.  
Keywords: Solubility enhancement, Liquisolid Compact. 
1. Introduction  
Solubility of drugs is a major factor in the 
design of pharmaceutical formulations lead to variable 
oral bioavailability. Dissolution is an important factor for 
absorption of drugs especially in case of water insoluble 
or poorly soluble drugs.  
The new developed technique by Spireas liqui-
solid system improves the dissolution properties of water 
insoluble or poorly soluble drugs. The term “liqui-solid 
systems” (LS) is a powdered form of liquid drug 
formulated by converting liquid lipophilic drug or drug 
suspension or solution of water-insoluble solid drug in 
suitable non-volatile solvent systems, into dry  looking, 
non-adherent, free-flowing and readily compressible 
powdered mixtures by blending with selected carrier and 
coating materials. [1,2] 
1.1 Theory of liquid solid systems [3-4]  
A powder can retain only limited amounts of 
liquid while maintaining acceptable flow and 
compression properties. To calculate the required 
amounts of powder excipients (carrier and coating 
materials) a mathematical approach for the formulation 
of liqui-solid systems has been developed by Spireas. 
This approach is based on the flowable (Ф- value) and 
compressible (Ψ-number) liquid retention potential 
introducing constants for each powder/liquid 
combination.  
1.2 Concept of liquisolid technology [5]  
When the drug dissolved in the liquid vehicle is 
incorporated into a carrier material which has a porous 
surface and closely matted fiber in its interior such as 
cellulose, both absorption and adsorption take place. The 
liquid initially absorbed into the interior of the particle is 
captured by its internal surface. After saturation, 
adsorption of the liquid onto the internal and external 
surface of the porous carrier particle occurs. Then, 
coating material provides the desirable flow property to 
the liquisolid system due to its high adsorptive properties 
and large surface area.  
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Figure 1: Concept of liquisolid compacts 
 
 2. Method of preparation [6-7]  
Calculated quantities of drug are added to the non-
volatile solvent, and then it is heated to dissolve the drug. 
This liquid drug solution is added to the carrier and coating 
materials and then it is mixed properly. The mixing process 
is carried out in three steps as described by Spireas et al.   
 The system is blended at a rate of one rotation per second 
for approximately one minute in order to distribute the 
drug evenly in liquid.   
 This admixture is evenly spread over the motor surface 
and left standing for 5min.to absorbs the drug into the 
powder particle.   
 Then powder is scraped off and then blended with other 
excipients for another 30 sec. similar to first step. This 
gives the final formulation of liquisolid tablets.  
 
3. Mechanism of action [8-9]   
3.1 Increased in surface area 
The drug within the liqui-solid system is in 
molecularly dispersed state. So, the    surface area of drug 
available for release is much greater than that of drug 
particles within directly compressed tablets.  
3.2 Increased in wettability 
Due to the fact that the liquid vehicle can either act 
as surface active agent or has a low surface tension, wetting 
of the liqui-solid primary particles is improved. Wettability 
of these systems has been demonstrated by measurement of 
contact angles and water rising times.  
3.3 Increased in  aqueous solubility of drug   
The relatively small amount of liquid vehicle in a 
liqui-solid compact is not sufficient to increase the overall 
solubility of the drug in the aqueous dissolution medium. 
However, at the solid/liquid interface between an individual 
liqui-solid primary particle and the release medium it is 
possible that in this microenvironment the amount of liquid 
vehicle diffusing out of a single liqui-solid particle together 
with the drug molecules might be sufficient to increase the 
aqueous solubility of the drug if the liquid vehicle acts as a 
cosolvent.  
 
4. Classification of liqui-solid systems [10-11]  
1) Powdered drug solutions  
2) Powdered drug suspensions  
3) Powdered liquid drugs  
4) Powdered drug emulsion   
 
5. Formulation components [5-8]  
The major formulation components of liqui-solid 
compacts are:  
5.1 Drug :  
It should be of bcs class II and IV. It should be 
lipophilic in nature.   
5.2 Non volatile solvents :  
They decreased the interfacial tension between the 
drug and dissolution medium.  
5.3 Carrier Material  
Relatively large, preferably porous particles 
possessing a sufficient absorption property which 
contributes in liquid absorption.  e.g. various grades of 
cellulose, starch22, lactose25, sorbitol etc.  
5.4 Coating Material  
These are flow-enhancing, very fine (10 nm to 
5,000 nm in diameter), highly adsorptive coating particles. 
e.g., silica of various grades like Cab-O-Sil M5, Aerosil 
200, Syloid 244FP etc.) Inert, high boiling point, preferably 
water-miscible and not.  
5.5 Disintegrants  
Most commonly used disintegrant is sodium starch 
glycolate (Explotab13, Pumogel, etc.)  
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6. Evaluations parameters [1-6]  
6.1 Pre-formulation studies:  
6.1.1 Solubility study:   
Solubility study is done by preparing a saturated 
solution of the drug in non-volatile solvents & analyzing 
them by using a spectrophotometer. Saturated solutions are 
prepared by adding excess amount of drug to vehicles and 
let it stay to achieve the equilibrium state (e.g., by shaking, 
stirring) for a specific time of period. Solvents with greater 
ability to solubilize the drug are selected for the formulation 
of liquisolid system for enhanced release.  
6.1.2 Determination of angle of slide (ɵ):   
Angle of the slide is determined to evaluate the 
flow property of powder excipients. The required amount of 
carrier is weighed and placed on one side of a metal plate 
with polished surface. The end is gradually raised till the 
plate become angular to the horizontal at which powder is 
about to slide. This angle is known as the angle of the slide. 
The angle of slide of 330 is regarded as an optimum flow 
behavior for compressing in to tablet or filling in capsules.  
6.2 Pre-compression studies:  
6.2.1 Flow property:  
The angles of repose, compressibility index, 
Hauser’s ratio are determined for evaluation of flow 
property of resulting final liquisolid powder.  
6.2.2 Differential Scanning Calorimetry (DSC):  
It is used to determine any possible interaction 
between excipients used in the formulation. There is an 
indication that the drug is in the form of solution in 
liquisolid formulation if the characteristic peak of the drug 
is absent in the DSC thermogram.  
6.2.3 X-ray diffraction (XRD) and Scanning Electron 
Microscopy (SEM):  
XRD & SEM studies are recommended to control 
the crystallinity of the drug. Disappearance of characteristic 
peak or crystals of the drug generally indicates that the drug 
is converted into the amorphous form or is solubilized in 
the liquisolid formulation.  
6.3 Post compression studies  
6.3.1.Thickness and Hardness test:  
The thickness of the tablets was determined using 
a digital caliper; reading shown was noted. The hardness 
was tested by using Monsanto tester.  
6.3.2 Friability test 
The friability of the tablets was determined using 
Roche friabilator.  
The % friability was then calculated using the 
formula:  
% friability =       Initial Weight – Final Weight 
                           --------------------------------------- *100 
                                          Initial Weight 
 
6.3.3 Weight variation test:  
The test was performed as per USB by weighing 
20 tablets individually on electronic balance, calculating the 
average weight, and comparing the individual tablet 
weights to the average.  
6.3.4 In-vitro dispersion time:   
In-vitro dispersion time was measured by 
following procedure. The tablet was then carefully 
positioned in the center of the petri dish containing 6 ml of 
water and the time required for the tablet to completely 
disintegrate into fine particles was noted. Three tablets from 
each formulation were randomly selected and In-vitro 
dispersion time was measured.  
6.3.5 In-vitro disintegration test:   
The test was carried out on 6 tablet using a tablet 
disintegration tester. Water at 37 ± 2 °C was used as a 
disintegration medium and the time taken for the complete 
disintegration of the tablet was noted with no palpable mass 
remaining in the apparatus was measured.  
6.3.6 In-vitro release studies:  
The dissolution rate of formulations was measured 
in dissolution test apparatus using USB type II. Dissolution 
studies were carried out using 900 ml of Phosphate buffer 
pH 7.4 at 37±0.5 °C at 50 RPM. 5 ml samples were 
withdrawn at various time intervals and placed by 5 ml 
fresh phosphate buffer pH 7.4 to maintain sink condition. 
The solutions were immediately filtered through filter 
paper, diluted and the concentration of the drug was 
determined spectrophotometrically.  
6.3.7 Wetting time:   
A piece of tissue paper was folded and placed 
twice and placed in a small petri dish containing sufficient 
water. A tablet was kept on the paper and the time for 
complete wetting of the tablet was measured.  
6.3.8 Water absorption ratio (R):  
The weight of the tablet prior to placement in the 
petri dish was noted (Wb). The wetted tablet was removed 
and weighed (WA). Water absorption ratio, R, was then 
determined according to the following equation.  
                   R=100 × (Wa-Wb)/Wb  
Where, Wb and Wa are tablet weights before and 
after water absorption, respectively  
6.3.9 Stability studies:  
Whenever a new formulation is developed, it is 
very essential to establish that the therapeutic activity of the 
drug has not undergone any change. To confirm this, the 
selected formulations were subjected to stability studies. 
Accelerated stability testing studies were performed for 6 
months as per ICH guidelines. The optimized formulations 
were kept at 40±2 °C and 75±5% RH. Tablets were 
evaluated for physical appearance, hardness, In-vitro 
dispersion time, % drug content and % drug release.  
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